CD47 and cancer: In recent years, multiple reagents targeting the CD47-SIRPα axis raised and showed a remarkable antitumor efficacy in multiple solid tumors, some of which were already at the phase I study, supporting the essential effect of regulating the CD47-SIRPα signal in cancer immunotherapy (28, 41, 42).